Cas:90585-88-9 (5-methyl-1,2-oxazol-3-ylidene)-nitrosomethanamine manufacturer & supplier

Chemical Name:(5-methyl-1,2-oxazol-3-ylidene)-nitrosomethanamine

CAS.NO:90585-88-9

Synonyms:N’-Hydroxy-5-methylisoxazole-3-carboximidamide;N-hydroxy-5-methyl-isoxazole-3-carboximidic acid amide

Molecular Formula:C₅H₇N₃O₂

Molecular Weight:141.12800

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:384.8ºC at 760mmHg

Density:1.51g/cm3

Index of Refraction:1.627

PSA:84.64000

Exact Mass:141.05400

LogP:0.77780

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N’-Hydroxy-5-methylisoxazole-3-carboximidamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-hydroxy-5-methyl-isoxazole-3-carboximidic acid amide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N’-Hydroxy-5-methylisoxazole-3-carboximidamide Use and application,N’-Hydroxy-5-methylisoxazole-3-carboximidamide technical grade,usp/ep/jp grade.

Related News: Government prosecutors often consider whether a corporation made a genuine effort to investigate and address potentially illegal activities once learning of them. (5-methyl-1,2-oxazol-3-ylidene)-nitrosomethanamine manufacturer The technology supports breakthroughs in medical research and is widely used by major global pharmaceutical companies to advance drug discovery & development and provide data to support regulatory submissions. (5-methyl-1,2-oxazol-3-ylidene)-nitrosomethanamine supplier Government prosecutors often consider whether a corporation made a genuine effort to investigate and address potentially illegal activities once learning of them. (5-methyl-1,2-oxazol-3-ylidene)-nitrosomethanamine vendor The number of Americans living with Alzheimer’s is expected to more than double to around 13 million by 2050, according to the Alzheimer’s Association. (5-methyl-1,2-oxazol-3-ylidene)-nitrosomethanamine factory First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s.